HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT)
Clinical trials for HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) explained in plain language.
Never miss a new study
Get alerted when new HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) trials appear
Sign up with your email to follow new studies for HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug aims to keep leukemia in remission after transplant
Disease control Recruiting nowThis study tests whether a daily pill called ivosidenib can help prevent acute myeloid leukemia (AML) from coming back after a stem cell transplant. It is for people with a specific IDH1 gene mutation. About 75 participants will receive either ivosidenib or a placebo for up to tw…
Matched conditions: HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT)
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated May 15, 2026 11:52 UTC
-
New inhaled drug aims to shield vulnerable patients from deadly lung infections
Disease control Recruiting nowThis study tests an experimental inhaled drug called PUL-042 in 100 people with blood cancers (like leukemia or lymphoma) or those who have had a stem cell transplant. Participants have a viral lung infection (PIV, hMPV, or RSV). The goal is to see if PUL-042 can prevent the infe…
Matched conditions: HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT)
Phase: PHASE2 • Sponsor: Pulmotect, Inc. • Aim: Disease control
Last updated May 14, 2026 12:06 UTC